Core Insights - Amarin Corporation will present new findings at the American Heart Association's Scientific Sessions 2025, reinforcing the efficacy of VASCEPA®/VAZKEPA® in cardiovascular risk reduction and highlighting the pleiotropic mechanism of action of Eicosapentaenoic Acid (EPA) [1][2] Group 1: Study Findings - New analyses from the REDUCE-IT study will evaluate the clinical benefit of Icosapent Ethyl (IPE) on cardiovascular outcomes with or without baseline use of aspirin [2] - Mechanistic studies will explore the anti-oxidant effects of EPA on lipoprotein(a) [Lp(a)] and its anti-inflammatory and endothelial-protective properties [2] Group 2: Presentation Details - Featured abstracts will be presented by academic collaborators, including a session on the efficacy of Icosapent Ethyl for cardiovascular risk reduction by aspirin use in REDUCE-IT [7] - Additional presentations will cover the effects of EPA on endothelial cells during inflammation and its impact on lipoprotein oxidation [5][8] Group 3: Company Overview - Amarin is a global pharmaceutical company focused on reducing the cardiovascular disease burden and advancing cardiovascular care, with a direct sales approach in the U.S. and an indirect distribution strategy internationally [5] - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising icosapent ethyl, launched in January 2020 for high-risk patients with persistent cardiovascular risk [6][9]

Core Insights - Amarin Corporation, in collaboration with HLS Therapeutics, will present scientific data on Icosapent Ethyl (IPE) at the Canadian Cardiovascular Congress (CCC) from October 23 to 26, 2025, emphasizing their commitment to advancing cardiovascular care [1][2] Group 1: Scientific Presentations - Data presented at CCC 2025 will highlight the clinical value of IPE for cardiometabolic conditions and explore the mechanistic effects of EPA on atherogenic lipoproteins and endothelial cells during inflammation when combined with a GLP-1 receptor agonist [2] - Featured abstracts include a poster presentation on the ENCORE study, which indicates that Icosapent Ethyl reduces cardiovascular disease risk in patients with cardiovascular-kidney-metabolic syndrome [2][3] - An oral presentation will discuss the effects of Icosapent Ethyl on the risk and duration of hospitalizations and death in the REDUCE-IT study [3] Group 2: Product Information - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising IPE, launched in the U.S. in January 2020 for high-risk patients with persistent cardiovascular risk despite statin therapy [7] - Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans [7] - VASCEPA is approved and sold in multiple countries, including Canada, China, Australia, and various European nations under the brand name VAZKEPA [7]